Introduction
Breast cancer is the most common malignancy in women, with increasing incidences noted worldwide. Since breast cancer is relatively sensitive to chemotherapy, chemotherapy usually plays a crucial role in systemic treatments of breast cancer, which is not replaceable by other measures, such as surgery and radiation therapy. However, development of multi-drug resistance (MDR) decreases chemotherapy efficacy. Furthermore, tumors in patients usually have varying sensitivity to chemotherapy, especially the drug dosage level. Therefore, reducing the necessary dosage level and increasing chemotherapy efficacy become more and more important in clinics.
Osteopontin (OPN) is a secreted glycophosphoprotein expressed in a number of cell types, such as epithelial lineages and leukocytes. It is involved in multiple processes, including tumor growth, metastasis, angiogenesis and immune system regulation (1, 2) . It regulates multiple cellular signal transduction pathways through binding to integrins (3, 4) . OPN has been detected in primary breast tumors, with elevated expression in the plasma of patients with metastatic breast cancer (5, 6) . OPN inhibits apoptosis of breast cancer cells and increases the migration of breast epithelial cells (7) (8) (9) (10) (11) (12) .
It has been reported that there is a relationship between OPN and chemotherapeutic drug resistance. Currently, studies are focused mainly on the relationship between high OPN expression and chemotherapeutic drug resistance (1, (13) (14) (15) (16) (17) (18) . However, there are no reports concerning the influence of OPN silencing on the resistance of doxorubicin, a commonly used chemotherapeutic drug for the treatment of cancers of the breast, bladder, stomach, lung, ovaries, thyroid, soft tissue sarcoma and multiple myeloma.
RNA interference (RNAi) mediated by microRNAs (miRNAs) or siRNAs is often used in the inhibition of gene expression and research of gene functions. In this study, we found that RNAi down-regulates OPN expression and increases the sensitivity of the MDA-MB-231 breast cancer cell line to doxorubicin. Immunoblot analysis. Total protein was extracted using cell lysis buffer. The total protein concentration was measured by the Bradford method. The protein was separated on 10% SDS PAGE gels. Immunoblot analyses were performed using primary anti-OPN monoclonal antibody (1:200), antiactin antibody (1:10,000) and the secondary mouse antibody (1:10,000).
Materials and methods

Reagents
Flow cytometry. Cells (10 5 ) in the logarithmic phase were collected and washed twice with PBS. After being fixed for 48 h at 4˚C with 1 ml of pre-cooled ethanol, the cells were washed twice with PBS and then resuspended in PBS. After adding 500 µl of PI (protein inhibitor) and RNaseA and incubating for 1 h, cell cycle and apoptosis were detected by flow cytometry.
Cell senescence test. Cells were washed once with PBS, and then fixed for 15 min at room temperature by adding 500 µl of β-galactosidase staining solution. After removing the staining solution, 500 µl dye solution was added, followed by incubation overnight at 37˚C. Cell staining was observed using microscopy. Qualitative analysis of cell senescence was performed.
MTT. Cells were placed in 96-well plates (4x10 3 /well). After 24 h, the DMEM medium was replaced with fresh medium. Then, 20 µl of 5 mg/ml MTT was added at 14, 48, 72 and 96 h, followed by incubation for 4 h. The cells were collected by centrifugation, and then resolved in 150 µl of DMSO, followed by incubation for 10 min with shaking. The absorbance (A) value at 490 nm was measured, and the cell proliferation curve was constructed.
Determination of cell proliferation inhibition rate (IR) was performed as follows: Cells in the transfected group, nontransfected group and negative transfected group were treated with a series of different concentrations of doxorubicin (0, 0.2, 0.4, 0.8, 1.6 and 3.2 µg/ml) for 48 h. The A value was measured using the same method as mentioned above.
IR was calculated as follows: IR = (1 -A value test group / A value control group ) x 100%. The half inhibition concentration (IC 50 ) of doxorubicin was also calculated.
Statistical analysis. The experimental data are expressed as the means ± standard error (SEM). Statistical software (SPSS 12.0) was used for independent sample t-tests, followed by the one-way analysis of variance. P-value <0.05 was considered to denote a significant difference. (Fig. 2) . These results suggested that OPN shRNA transfection causes a significant S phase arrest of cells. The apoptotic rate of MDA-MB-neg was 3.61%, while that of MDA-MB-343 was 4.91%, suggesting that OPN down-regulation affects apoptosis slightly, if any (Fig. 3) .
Results
Down-regulated expression of OPN in MDM-
OPN gene down-regulation increases cell senescence.
Cell senescence is a mechanism often related to tumor development. β-galactosidase staining was used to detect the cell senescence of MDA-MB-neg and MDA-MB-343 cells (Fig. 4) . As shown in Fig. 4 , OPN down-regulation increases cell senescence.
OPN gene down-regulation decreases cell proliferation.
Proliferation of MDA-MB-231, MDA-MB-neg and MDA-MB-343 cells was measured using the MTT method at time points including 24, 48, 72 and 96 h. As shown in Fig. 5 , when compared to MDA-MB-231 and MDA-MB-neg cells, the growth of MDA-MB-343 cells was significantly reduced. Therefore, these results suggest that OPN gene downregulation decreases cell proliferation.
Down-regulation of the OPN gene increases the sensitivity of breast cancer cells to doxorubicin.
To determine whether down-regulation of OPN affects the sensitivity of the MDA-MB-231, MDA-MB-neg and MDA-MB-343 cells to doxorubicin, these cells were treated with different concentrations of doxorubicin (0.2, 0.4, 0.8, 1.6 and 3.2 µg/ ml) for 48 h, followed by cell proliferation measurements using the MTT assay. The absorbance value at 490 nm was protein in MDA-MB-231 breast cancer cells, reduced cell proliferation and increased their sensitivity to doxorubicin.
The senescence test results showed that OPN down-regulation increased cell senescence, which is consistent with the results reported by Shevde et al (19) . The three groups of cells, including MDA-MB-231, MDA-MB-neg and MDA-MB-343 cells, were treated with different concentrations of doxorubicin. The doxorubicin IC 50 value of the MDA-MB-343 group was 0.13588 µg/ml, while the doxorubicin IC 50 of the MDA-MB-231 and MDA-MB-neg groups was 0.83869 and 0.79652 µg/ ml, suggesting that down-regulation of OPN increases the sensitivity of the cells to doxorubicin.
Previous reports indicate that when OPN binds to the integrin αβ1 (an extracellular matrix ligand), the PI-3K/Akt pathway is activated, leading to generation of resistance to chemotherapy (20) (21) (22) (23) . OPN interference inhibits the activation of the PI-3K/Akt signaling pathway, so that the sensitivity of cells to chemotherapeutic drugs increases. In addition, S phase arrest in the cell cycle and decreases in cell proliferation were found upon down-regulation of OPN in our study. However, the specific mechanism remains unclear and should be further investigated. Doxorubicin is one of the most commonly used chemotherapy drugs for treating breast cancers. Yet, one side effect is cardiac toxicity, which is due to the cumulative dose of the drug. Our finding that the sensitivity of breast cancer cells to doxorubicin significantly increased when OPN expression was down-regulated suggests that the drug dose can be reduced when OPN expression is decreased. By this manner, the cumulative dose of drugs would be largely reduced, which will be helpful for the treatment with doxorubicin of breast cancer patients.
In conclusion, the present study demonstrates that RNAi effectively inhibits OPN expression, which is beneficial to breast cancer gene therapy. Our results indicate that OPN also inhibits breast cancer cell proliferation and facilitates cell senescence, resulting in a synergistic effect in combination with doxorubicin. Therefore, our study provides a basis for continued research for the treatment of breast cancer.
